Archive
540 articles, sorted by publication time.
The collaboration, worth up to $600 million, brings generative AI drug design back into the core R&D process of a major pharmaceutical company; the real test is not whether algorithms can propose molecules, but whether drug candidates can withstand clinical and regulatory scrutiny.
As candidate molecules move toward manufacturable medicines, cell line development is a narrow gate that new cancer therapies must pass before leaving the laboratory; VERAXA’s latest progress brings its BiTAC platform into the practical test of quality, consistency, and scale-up production.
From molecular generation to human data, the narrative around AI drug discovery is changing; the key question in 2026 is no longer whether a model can propose a drug candidate, but whether it can hold up under the realities of clinical testing, regulation, and manufacturing.
As patents on blockbuster drugs expire one after another, global drugmakers are more actively turning to Chinese AI drug-design companies for candidate molecules and R&D efficiency. But behind the dealmaking surge, scientific validation, clinical risk, and geopolitical scrutiny remain at the same table.
Early clinical news has pushed Trinity Biotech back into the blood glucose monitoring race; but before the data details are fully disclosed, this looks more like preliminary support for a product roadmap than a sign that the market outcome has been decided.
If divarasib can translate its clinical advantage into regulatory approval, it would bring a new oral targeted option to patients with KRAS G12C-mutated lung cancer; but with limited information in the news summary, the magnitude of efficacy, safety, and complete trial data remain key to interpretation.
Divarasib has produced positive results in a pivotal clinical trial, bringing a new potential treatment option for a group of lung cancer patients with a specific KRAS mutation; however, before full data are released, the magnitude of efficacy, safety, and future regulatory path remain to be clarified.
As antibody-drug conjugates, bispecific antibodies, and novel biologics move into the clinic, the role of contract manufacturers is shifting from outsourced production plants to development partners that jointly unpack risk.
If the FDA’s latest decision does indeed lower the eligible age further, this is not just an extension of the gene therapy market, but a difficult question pediatric medicine must confront: when is it worth using an intensive, one-time treatment in exchange for the possibility of rewriting years of disease burden?
Multiple observational analyses at ASCO show lower-risk signals among GLP-1 receptor agonist users in breast cancer incidence, mortality, and metastatic progression in some cancers; this is not a definitive conclusion that they are anticancer therapies, but it makes the links among metabolism, obesity, and tumor biology harder to ignore.
The focus of this collaboration is not simply to introduce algorithms into drug design, but to bind the generation, screening, and experimental judgment of early candidate molecules into a single process, testing whether AI can truly shorten the trial-and-error period at the front end of R&D.
As demand for biologics contract development and manufacturing fluctuates, this appointment is more than a corporate handover. It also reflects how biomanufacturing in Europe and the United States is readjusting global footprints, customer trust, and execution rhythm.